Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS extension study of ianalumab in Sjögren’s syndrome
2022-502966-26-01Phase 3Authorised
- Sponsor
- Novartis
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in Sjögren's syndrome (3 arms), sponsored by Novartis. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Planned start Oct 2023; status: authorised.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2022-502966-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502966-26-01.